EVOTEC SE INH O.N.
Commented by André Will-Laudien on October 24th, 2024 | 07:30 CEST
Biotech – Are takeovers looming amidst curious prices? Evotec, Bayer, Vidac Pharma and BioNTech in the spotlight
The biotech sector is once again in the spotlight. Since the acquisition of MorphoSys at the beginning of the year, the speculation carousel is turning again. Is Evotec next, or maybe Vidac Pharma? The Hamburg-based drug specialist came under fire from short-sellers after the resignation of long-standing CEO Lanthaler, who had shorted over 4% of the capital by mid-September. However, the price stubbornly held above the EUR 5 mark, and yesterday saw a 10% rise to EUR 6.60. What is behind this? Last week, it was Vidac Pharma that surged 300% from a standing start with enormous trading volumes. The thought processes of market participants are evident: interest rates are falling, making refinancing attractive again for upcoming financial investors. We shed light on the key players.
Read
Commented by Armin Schulz on October 23rd, 2024 | 08:00 CEST
Evotec, Nyxoah, BioNTech – Stocks for the future?
The biotechnology and medtech industries are at an exciting turning point, with companies such as Evotec, Nyxoah and BioNTech positioning themselves as leading players in this dynamic field. Their innovative technologies and promising product pipelines could have the potential to fundamentally transform healthcare. Evotec excels in drug discovery expertise, Nyxoah develops groundbreaking solutions for sleep apnea, and BioNTech is a pioneer in mRNA technology. Although Evotec and BioNTech have recently faced challenges, all three companies are well-positioned to benefit from future medical developments.
Read
Commented by Fabian Lorenz on October 17th, 2024 | 07:00 CEST
Big News for Nel, Evotec, and dynaCERT! Stock set for +100% or -20%?
Big news for Evotec. The analysts at Warburg see more than 100% upside potential. At the same time, however, they are warning of weak quarterly figures. Deutsche Bank even predicts a potential price drop. A long-awaited breakthrough came for dynaCERT. With VERRA's certification of HydraGEN products, trading in CO2 certificates is now possible, enabling new revenue opportunities for customers and dynaCERT. This could allow both dynaCERT and its stock to grow to a new level. At Nel, growth is slowing, and losses remain high. Is there any reason for hope?
Read
Commented by Stefan Feulner on October 14th, 2024 | 07:00 CEST
Bayer, Vidac Pharma, Evotec – Enormous potential
Since the US Federal Reserve cut key interest rates and signaled a continuation of its loose monetary policy, the Nasdaq Biotech Index has been on an upward trajectory and has significantly outperformed the broader market in recent days. The correction of the past few months seems to be over in this sector, and the all-time high from August 2021 is within reach. In addition to rising share prices, the number of acquisitions is also increasing significantly, a sign of the undervaluation of many listed companies.
Read
Commented by Armin Schulz on October 2nd, 2024 | 07:00 CEST
Evotec, Nyxoah, Carl Zeiss Meditec – Biotech and medtech stocks with potential
The biotechnology and medical technology industries are driving medical innovation and offering exciting investment opportunities. Evotec, Nyxoah, and Carl Zeiss Meditec stand out among the companies that are particularly prominent in these areas. Evotec has established itself through its collaborative strategy in drug discovery and is using modern technologies such as AI to accelerate the discovery process. The emerging medtech company Nyxoah is focusing on innovative solutions for the treatment of sleep apnea. Carl Zeiss Meditec is a leader in ophthalmology and microsurgery with world-class optical devices and advanced visualization technologies. All three companies have recently seen their stock prices come under pressure and now offer an entry opportunity.
Read
Commented by André Will-Laudien on September 27th, 2024 | 07:00 CEST
150% turnaround likely! TUI, Saturn Oil + Gas, Plug Power, Novo Nordisk, and Evotec in focus
With the FED's latest interest rate cut, the way is paved for higher prices. In addition to the main performers, investors are increasingly turning their attention to equities that have so far seen little appreciation. The key question here is when the fundamentals will ultimately improve. This could then ensure that the analysts' bias finally turns and positive assessments are possible again. TUI, Evotec, and Plug Power are currently at very interesting points, while Saturn Oil & Gas is delivering results consistently and is now being recognized by institutional investors. Where are the opportunities for investors?
Read
Commented by André Will-Laudien on September 25th, 2024 | 07:00 CEST
The biotech rally of the century is on the horizon! 150% returns with BioNTech, Pfizer, Nyxoah, Bayer, or Evotec?
The stock market keeps climbing, and now it is moving even faster with a double-whammy interest rate cut from the Fed! In a surprising move, the US Federal Reserve pulls a 0.5% rate cut from its magic hat, boosting market sentiment. Now, it is certain that life will continue in the biotech sector. However, selecting the right stocks remains challenging. With a medium-term focus, paying attention to management quality is important because the recent price declines were too high in some cases. However, some research approaches promise a better future. BioNTech, Pfizer, and Bayer have already bottomed out. Nyxoah and Evotec are now showing the first signs of breaking out after a period of consolidation. What is the short-term outlook?
Read
Commented by André Will-Laudien on September 18th, 2024 | 07:30 CEST
Turnaround stocks – Here we go! 250% returns with thyssenkrupp, nucera, Evotec, VCI Global and A2Z Cust2Mate
The stock markets are going up and up, even in the most challenging stock market month of the year. Because the market had already corrected in July, the bulls say that the need to catch up is all the greater due to upcoming interest rate cuts by central banks. The bears believe that the valuation of tech and AI stocks, in particular, is already far too advanced and are hoping for a correction. Yet, green signals dominate daily, and now the question is which lagging stocks to invest in. Of course, it does not work without fundamentals, but sometimes insider buying is enough to lift sentiment. We select promising risk-return profiles for risk-conscious investors.
Read
Commented by André Will-Laudien on September 16th, 2024 | 07:15 CEST
This is unbelievable! 250% with an announcement: Bayer, Vidac Pharma, Evotec, and Valneva
The stock market has been rallying week after week, yet the biotech sector stubbornly lags behind. However, with the first interest rate cut in Europe, the path of lower financing options has now also been mapped out for the US. This week, the FED is set to decide on rate cuts, with 87% of capital market experts expecting a total of three cuts by the end of the year. That would be grist to the mill for growth stocks. Vidac Pharma has already gained 50% in 2 months, and Bayer and Evotec will likely follow soon. Valneva is raising EUR 61 million and aims to break even operationally. What is next for the sector?
Read
Commented by Fabian Lorenz on September 5th, 2024 | 09:15 CEST
Bargain alert in Biotech, AI, Cannabis: Evotec, Cantourage, BlockchainK2 share instead of Nvidia?
The weak late summer months on the stock market often offer opportunities for bargain hunters - including at the moment and away from the large caps. For instance, Nvidia has already lost around 30% from its all-time high, but historically a drop of 50% or more is not uncommon for this AI high-flyer. It is, therefore, worth taking a look at fallen small and mid-caps. For example, Cantourage shares gained more than 10% yesterday alone. Is there more to come for the cannabis stock? BlockchainK2 shares are also ripe for a price surge. The SaaS platform for financial service providers offers cost and efficiency benefits thanks to blockchain and AI. The sentiment for fintechs - look at PayPal - is currently brightening noticeably, and BlockchainK2 is a takeover candidate. The same could be said for Evotec, or is there a risk of a slide to EUR 4? In any case, the Company is not finding any peace.
Read